| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |